GKOS241220C145000
- 1.60
- -3.90-70.91%
Glaukos Newsroom
Glaukos Cut to Underweight From Equal-Weight by Morgan Stanley
Glaukos Price Target Announced at $120.00/Share by Morgan Stanley
Morgan Stanley Downgrades Glaukos(GKOS.US) to Sell Rating, Maintains Target Price $120
Glaukos Is Maintained at Buy by BTIG
Glaukos Analyst Ratings
BTIG Maintains Glaukos(GKOS.US) With Buy Rating, Raises Target Price to $149
Stifel Maintains Glaukos(GKOS.US) With Buy Rating, Maintains Target Price $145
Truist Financial Maintains Glaukos(GKOS.US) With Buy Rating
Mizuho Securities Maintains Glaukos(GKOS.US) With Hold Rating
Uncertain Growth and Reimbursement Challenges Keep Glaukos's IDose at Hold Rating
Glaukos Is Maintained at Overweight by Wells Fargo
Glaukos Analyst Ratings
Stifel Maintains Glaukos(GKOS.US) With Buy Rating, Maintains Target Price $145
A Quick Look at Today's Ratings for Glaukos(GKOS.US), With a Forecast Between $140 to $149
Glaukos (GKOS) Receives a Buy From Piper Sandler
Analysts Offer Insights on Healthcare Companies: Glaukos (GKOS) and Vertex Pharmaceuticals (VRTX)
Glaukos' Strong Q3 2024 Performance and IDose's Growth Propel Buy Rating
Jefferies Maintains Glaukos(GKOS.US) With Buy Rating, Raises Target Price to $155
Truist Financial Maintains Glaukos(GKOS.US) With Buy Rating
Analysts Conflicted on These Healthcare Names: Medpace Holdings (MEDP), McKesson (MCK) and Glaukos (GKOS)